Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Commentary
  • Published:

The ADAMs: a new therapeutic avenue?

The Pharmacogenomics Journal volume 2, pages 73–74 (2002)Cite this article

The sufficiency of ADAM blockade in preventing cardiac hypertrophy and uncovering the mechanism of ADAM action in triggering hypertrophy presents a new opportunity to design effective therapeutics aimed at preventing the progression of heart disease to heart failure.

Seventeen million people will die this year of complications related to cardiovascular disease (CD). In the United States alone, nearly 62 million individuals currently suffer from some form of CD, resulting in an average of one death every 33 seconds. Various etiologies, such as elevated blood pressure or mutations in the contractile and cytoskeletal proteins, result in cardiac hypertrophy. Initially, myocardial hypertrophy relieves wall stress under hypertensive conditions and is thought of as a compensatory response, but it is not clear whether hypertrophy is intrinsically beneficial to long-term survival. The Framingham Heart Study shows an association between cardiac hypertrophy and mortality1 and recent data using animal models indicate that hypertrophy can actually be deleterious and hasten the progression to heart failure.2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Levy D et al . N Engl J Med 1990 322: 1561–1566

  2. Esposito G et al . Circulation 2002 105: 85–92

  3. Rockman HA et al . Nature 2002 415: 206–212

  4. Wettschureck N et al . Nat Med 2001 7: 1236–1240

  5. Izumi Y et al . EMBO J 1998 17: 7260–7272

  6. Asakura M et al . Nat Med 2002 8: 35–40

  7. Black RA, White JM . Curr Opin Cell Biol 1998 10: 654–659

  8. Fujino T et al . Cardiovasc Res 1998 38: 365–374

  9. Perrella MA et al . J Biol Chem 1994 269: 27045–27050

  10. Ducharme A et al . J Clin Invest 2000 106: 55–62

  11. Heymans S et al . Nat Med 1999 5: 1135–1142

  12. Iwamoto R, Mekada E . Cytokine Growth Factor Rev 2000 11: 335–344

  13. Iwamoto R et al . J Biol Chem 1999 274: 25906–25912

  14. Li YY et al . Proc Natl Acad Sci USA 2000 97: 12746–12751

  15. Spinale FG et al . Cardiovasc Res 2000 46: 225–238

  16. Zucker S et al . Oncogene 2000 19: 6642–6650

  17. Spinale FG et al . Circ Res 1999 85: 364–376

  18. Schneider JW et al . Semin Oncol 2001 28: 18–26

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Molecular Cardiovascular Biology, The Children's Hospital Research Foundation, Cincinnati, OH, USA

    G Schwartzbauer & J Robbins

Authors
  1. G Schwartzbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Robbins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Robbins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartzbauer, G., Robbins, J. The ADAMs: a new therapeutic avenue?. Pharmacogenomics J 2, 73–74 (2002). https://doi.org/10.1038/sj.tpj.6500098

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500098

Search

Advanced search

Quick links